Alto Neuroscience (NYSE:ANRO) Upgraded at Zacks Research

Alto Neuroscience (NYSE:ANRO) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other research analysts have also weighed in on ANRO. Robert W. Baird decreased their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. HC Wainwright raised their price target on Alto Neuroscience from $50.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 17th. Wolfe Research initiated coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Wedbush upped their price objective on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Finally, Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $34.36 on Thursday. The business’s 50 day moving average price is $27.36 and its two-hundred day moving average price is $23.39. The company has a market cap of $1.35 billion, a PE ratio of -14.20 and a beta of 1.06. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a twelve month low of $3.41 and a twelve month high of $35.41.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, analysts predict that Alto Neuroscience will post -2.68 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in ANRO. Northwestern Mutual Wealth Management Co. lifted its holdings in Alto Neuroscience by 14,567.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after purchasing an additional 211,222 shares during the last quarter. Jennison Associates LLC bought a new stake in Alto Neuroscience in the 1st quarter valued at $8,687,000. Orbimed Advisors LLC grew its holdings in Alto Neuroscience by 34.0% in the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock valued at $3,765,000 after buying an additional 42,500 shares in the last quarter. Perceptive Advisors LLC grew its holdings in Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after buying an additional 225,500 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Alto Neuroscience in the 1st quarter valued at $538,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.